Neuphoria Therapeutics Inc

NAS:NEUPHealthcarenasdaq_composite

——At close · Market cap — · Next earnings Wed 2 Dec

Neuphoria Therapeutics Inc · Valuation · TradingHolo

Shown only where the company is comparable with its peers

Multiple	Now	Sector median
P/E	−1.3×	−1.7×
Price / Book	0.7×	2.0×
Price / Sales	15.3×	3.9×
Price / Free cash flow	−1.4×	−1.6×
EV / EBITDA	0.1×	−1.2×
Earnings yield	−75.1%	−14.3%
Free cash flow yield	−69.0%	−9.9%

Price at the report date ÷ trailing twelve-month earnings

No comparable valuation history is available.

Same market and sector · market cap in USD

Company	Price	Change	Mkt cap (USD)	P/E	ROE	1Y
NYSE:LLYEli Lilly and Co · 🇺🇸 NYSE	—	—	—	56.6×	77.8%	+15.2%
NYSE:JNJJohnson & Johnson · 🇺🇸 NYSE	—	—	—	22.8×	32.9%	+32.1%
NYSE:ABBVAbbVie Inc · 🇺🇸 NYSE	—	—	—	118.2×	−129.2%	+24.6%
NYSE:UNHUnitedHealth Group Inc · 🇺🇸 NYSE	—	—	—	30.3×	12.8%	+14.1%
NYSE:MRKMerck & Co Inc · 🇺🇸 NYSE	—	—	—	19.4×	34.7%	+71.2%
NYSE:NVSNovartis AG · 🇺🇸 NYSE	—	—	—	19.7×	30.5%	+14.9%
NYSE:AZNAstraZeneca PLC · 🇺🇸 NYSE	—	—	—	24.8×	21.1%	−2.4%
NYSE:TMOThermo Fisher Scientific Inc · 🇺🇸 NYSE	—	—	—	37.3×	12.6%	+26.6%
NAS:AMGNAmgen Inc · 🇺🇸 NAS	—	—	—	29.8×	89.1%	+43.7%
NAS:GILDGilead Sciences Inc · 🇺🇸 NAS	—	—	—	22.3×	37.5%	+29.9%